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Laboratory of Intestinal Physiopathology, Department of Anatomy & Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada, J1H 5N4The canonical WNT signaling pathway is ultimately involved in the with tumor invasion andmetastasis via Bcl9/9l appear to be dispensable
regulation of cytoplasmic levels of free β-catenin. When inactive, the
β-catenin not incorporated in adherent junctions is captured by the
adenomatous polyposis coli (APC)-based protein complex, phosphory-
lated and then processed for degradation by the proteasome. Activation
by WNT ligands such as those found in the intestinal stem cell niche
located in the lower crypts prevents β-catenin ubiquitination allowing
its accumulation in the cytoplasm and shuttling to the nucleus
where it associates with the DNA-binding proteins of the lymphoid
enhancer-binding factor/T-cell factor (TCF) family to transactivate spe-
ciﬁc gene expression such asMYC, CCLD1 and other genes that drive cell
proliferation and stemness (Niehrs 2012). Colorectal cancer (CRC) cells
frequently display a constitutively active WNT–β-catenin signaling
pathway as a consequence of mutations in APC or other genes that en-
code the APC-based protein destruction complex or β-catenin itself,
which allows β-catenin to accumulate in the nucleus and contribute
to cellular transformation (Barker and Clevers 2006; Krausova and
Korinek 2014). There are many factors that interact and modulate the
WNT cascade in both normal and transformed cells. As depicted in
seminal reviews (Cruciat and Niehrs 2013; de Lau et al. 2014), WNT
signaling is strictly controlled at the ligand–receptor level by a series
of inhibitors and activators that regulate signal strength. Furthermore,
WNT signaling is also modulated at the transcriptional level by a series
of β-catenin-interacting co-factors such as cyclic AMP response
element-binding protein and B-cell lymphoma 9 (BCL9 and BCL9L)
which can strengthen the activity (Holland et al. 2013). While many
of these modulators of the WNT pathway represent potential targets
for cancer therapeutics, their disruption can also lead to alterations in
the WNT signaling pathway of healthy tissues, a difﬁculty that has to
be taken into consideration in the design of pre-clinical and, eventually,
clinical studies (Barker and Clevers 2006).
In this context, it is interesting to note that the impact of the cellular
response associated with the β-catenin co-factor BCL9/9L may be
context-dependent. Indeed, in the mouse, ablation of Bcl9/9l in the
intestinal epithelium abrogates the expression of genes related to
epithelial–mesenchymal transformation (EMT) and stemness in chem-
ically induced colorectal tumors suggesting that the traits associatedDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.10.030.
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In this issue of EBioMedicine, Moor et al. have further investigated
e importance of BCL9/9L on WNT signaling in CRC cells (Moor et al.
015). They ﬁrst investigated a second CRC mouse model driven by
ss of Apc and oncogenic Kras to complement their initial observations
erformed on the chemically induced mouse CRC model mentioned
bove (Deka et al. 2010) conﬁrming that ablation of Bcl9/9lmodulates
imilar alterations of gene expression in both types of tumors with
59 down- and 107 up-regulated common differentially expressed
enes. Analysis of the up- and down-regulated genes revealed a nega-
ve enrichment of genes related to intestinal WNT targets, stemness
nd EMT while differentiation-related genes were positively enriched.
terestingly, a search for human homologs allowed the characteriza-
on of a BCL9/9L-KO signature of 378 genes that was then used to
robe public human CRC databases revealing that hazards of relapse
nd death are both signiﬁcantly reduced in patients displaying BCL9/
L-KO-like tumor proﬁles. Then, using the organoid/mini-gut culture
ystem consisting of expanding epithelial stem cells isolated from the
tact intestine into three-dimensional structures (Sato and Clevers
013), they conﬁrmed that ablation of Bcl9/9l improves morphological
ifferentiation and generates a BCL9/9L KO-like signaturewithout alter-
g proliferation in vitro. Interestingly, subcutaneous grafting of the
ame organoids in immuno-compromised mice resulted in tumor re-
ression in allografts lacking Bcl9/9l while the wild-type organoids
rew exponentially, consistent with their Apc−/− and mutated Kras
ackground. Taken together, these results suggest that CRC cells are
ery dependent on functional BCL9 proteins for promoting tumor pro-
ression via stimulation of stemness and EMT traits and preventing dif-
rentiation, a pathway not apparently essential for the maintenance of
ormal intestinal epithelial homeostasis. The discovery that patients
ith tumors displaying gene expression proﬁles similar to the BCL9/
L-KO signature have a better prognosis than those with a BCL9/9L
ild-type phenotype is quite relevant to these ﬁndings. While this
oints out the interest of the β-catenin–BCL9/9L complex as a potential
erapeutic target for CRC, it also raises the need to validate, in the end,
e direct implication of BCL9/9L in the generation of the BCL9/9L-KO
ignature in human cells, considering the fact that BCL9/9L have been
und to be expressed in all tumor samples. Another key aspect that re-
ains to be investigated pertains to the possibly distinct implications of
CL9 and BCL9L. The ﬁndings from human CRC database analyses that
temness traits appear to correlate much more closely with BCL9Lthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
1847J.-F. Beaulieu / EBioMedicine 2 (2015) 1846–1847than BCL9 is noteworthy particularly in the contextwhere in themouse,
BCL9L over-expression appears to induce intestinal tumorigenesis and
promote expression of genes involved in EMT (Brembeck et al. 2011).
In summary, the results byMoor et al. show that inhibiting the BCL9/
9L interactionwithβ-catenin leads to diminished gene expression asso-
ciated with stemness and EMT traits and promotes differentiation in
CRC tumors (in the context as shown previously (Deka et al. 2010)
that it remains relatively well tolerated in the normal intestinal epithe-
lium). Taken in conjunctionwith the fact that the BCL9/9L-KO signature
in CRC tumors is associatedwith a better prognosis, the study points out
that the BCL9/9L–β-catenin complex represents a promising potential
therapeutic target for treating CRC.
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